Personalised therapy in follicular lymphoma – is the dial turning?

Author:

Linton Kim M.12ORCID,Specht Lena34ORCID,Pavlovsky Astrid56ORCID,Thompson Carrie A.7ORCID,Kimby Eva8ORCID,de Jong Daphne9ORCID,Nastoupil Loretta J.10ORCID,Cottereau Anne‐Ségolène11ORCID,Casulo Carla12ORCID,Sarkozy Clémentine13ORCID,Okosun Jessica14ORCID

Affiliation:

1. Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK

2. Division of Cancer Sciences The Manchester Cancer Research Centre University of Manchester Manchester UK

3. Department of Oncology Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark

4. Department of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

5. Department of Hematology Fundaleu Clinical Research Center Buenos Aires Argentina

6. Centro de Helmatología Pavlovsky Medical Director Buenos Aires Argentina

7. Department of Internal Medicine Division of Hematology Mayo Clinic Rochester Minnesota USA

8. Department of Medicine Karolinska Institutet Center of Hematology Stockholm Sweden

9. Department of Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

10. Department of Lymphoma/Myeloma University of Texas MD Anderson Cancer Center Houston Texas USA

11. Department of Nuclear Medicine Cochin Hospital APHP University of Paris Cité Paris France

12. Department of Medicine University of Rochester Rochester New York USA

13. Hematology Department Institut Curie Saint Cloud France

14. Centre for Haemato‐Oncology Barts Cancer Institute Queen Mary University of London London UK

Abstract

AbstractFollicular lymphoma is the most common indolent lymphoma accounting for approximately 20%–25% of all new non‐Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high‐risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging‐ and biomarker‐based tools will, in time, allow these gaps to be closed.

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3